Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 718 results for "Ibrutinib"

17 images for Ibrutinib

Targeted Oncology, 2 weeks ago
Pharmafile, 2 weeks ago
Cancer Therapy Advisor, 2 weeks ago
Nasdaq, 4 weeks ago
Pharmafile, 1 month ago
Cancer Therapy Advisor, 2 months ago
Irish Medical Times, 2 months ago
OncLive, 2 months ago
OncoTherapy Network, 2 months ago
MDLinx, 2 months ago

Janssen's IMBRUVICA®▼(ibrutinib) Approved by European Commission for Patients with Newly Diagnosed Chronic Lymphocytic Leukaemia

Approval based on data from Phase 3 RESONATE TM -2 trial showing once-daily, oral ibrutinib significantly improved overall and progression-free survival versus chemotherapy BEERSE, Belgium--(BUSINESS WIRE)-- Janssen-Cilag International NV ...
 CNBC4 weeks ago Janssen's IMBRUVICA®?(ibrutinib) Approved by European Commission for Patients with Newly Diagnosed Chronic Lymphocytic Leukaemia  Bloomberg4 weeks ago JANSSEN : 's IMBRUVICA®▼(ibrutinib) Approved by European Commission for Patients with Newly Diagnosed Chronic Lymphocytic Leukaemia  4 Traders4 weeks ago Janssen Receives Positive CHMP Opinion for IMBRUVICA (ibrutinib) for Expanded Use in Chronic Lymph  Global Hospital & Healthcare Management1 month ago
[x]  

EHA 2016: The influence of ibrutinib on ...

Loading........ 76 views Description: Simon Rule, MD from Derriford Hospital, Plymouth, UK outlines his presentation on his work with ibrutinib. Prof Rule discusses the outcome of a compilation of three trials involving the single-agent ...
 Oncology Tube5 days ago BRIEF-Janssen to present data from 6 compounds at 2016 ASCO annual meeting  Reuters UK1 month ago Pfizer says will present data on 6 drugs at ASCO meeting  Yahoo! Finance1 month ago Janssen to Present Data from Six Compounds Including Daratumumab and Ibrutinib at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting  WorldNetDaily1 month ago
[x]  

TG Therapeutics Reports TGR-1202 in Combo with Ibrutinib, Recaps Long-Term Safety, Efficacy Data of TGR-1202 in CLL, NHLs

TG Therapeutics, Inc. (NASDAQ: TGTX ) today announced data presented during the 21st Annual Congress of the European Hematology Association (EHA) being held in Copenhagen, Denmark. These presentations include long term follow-up data of TGR-1202, ...
 Benzinga.com2 weeks ago TG Therapeutics, Inc. Announces Data from TGR-1202 in Combination with Ibrutinib as well as Recaps Long-Term Safety and Efficacy Data of TGR-1202 in CLL and NHL at the 21st European Hematology Associa  International Business Times2 weeks ago TG Therapeutics, Inc. Announces Long-Term Follow-up of TGR-1202 Demonstrates a Differentiated Safety Profile and High Response Rates in CLL and NHL in Data Presented at the 52nd Annual Meeting of the  International Business Times3 weeks ago TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 21st European Hematology Association Annual Congress  International Business Times1 month ago
[x]  

AbbVie Gets Europe's Approval For IMBRUVICA For Chronic Lymphocytic Leukemia Treatment

AbbVie (NYSE: ABBV ) revealed Tuesday that the European Commission (EC) has given its approval for its IMBRUVICA (ibrutinib) as a first-line treatment option for adult patients with chronic lymphocytic leukemia (CLL). According to the company, the ...
 Benzinga.com4 weeks ago AbbVie, Janssen's Imbruvica gets European approval to teat CLL  Pharmafile4 weeks ago Janssen/AbbVie's Imbruvica boosted by US label update  pharmaphorum1 month ago AbbVie's Holistic Oncology Strategy May Drive Its Valuation Higher Still  Seeking Alpha3 weeks ago

Health Canada approves IMBRUVICA® (ibrutinib) as a treatment for Waldenström's Macroglobulinemia

TORONTO, ON Janssen Inc. reports that Health Canada has issued a Notice of Compliance (NOC) for IMBRUVICA® (ibrutinib), for the treatment of patients with Waldenström's macroglobulinemia (WM). WM is a rare, incurable type of non-Hodgkin ...
 BiotechnologyFocus.ca1 month ago Health Canada Approves IMBRUVICA (ibrutinib) for the Treatment of Waldenström's Macroglobulinemia  FirstWord Pharma1 month ago
[x]  

Acetylon Announces the Presentation of Preclinical Data at AACR Supporting the Use of Selective HDAC6 Inhibition to Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology

-Studies demonstrate potential mechanistic synergies with the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, as well as with immunomodulation- BOSTON--(EON: Enhanced Online News Overall these data further support the broad versatility and ...
 EON: Enhanced Online News2 months ago Acetylon Pharmaceuticals Announces The Presentation Of Preclinical Data At AACR Supporting The Use Of Selective HDAC6 Inhibition To Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology  BioSpace2 months ago
[x]  
Targeted Oncology

AbbVie Nabs Breakthrough Tag for Ibrutinib to Treat Chronic Graft-Versus-Host-Disease

Life Sciences Jobs
 BioSpace22 hours ago The success of ibrutinib in treating mantle cell lymphoma (MCL)  Oncology Tube1 day ago Ibrutinib Well Tolerated in Patients With Central Nervous System Lymphoma  ASH Clinical News2 weeks ago Ibrutinib shows added benefit for refractory mantle cell lymphoma patients  News-Medical.Net1 month ago
[x]  
Cancer Therapy Advisor

Ibrutinib at below standard dose may achieve good survival in CLL

0 Flares 0 Flares × Ibrutinib given at doses lower than the standard dose of 420 mg/day was associated with comparable overall survival and progression-free survival as the standard dose in patients with chronic lymphocytic leukemia (CLL), ...
 PM 3601 week ago Venetoclax Active in Relapsed/Refractory to Ibrutinib or Idelalisib CLL  Cancer Therapy Advisor2 weeks ago Venetoclax achieves responses in CLL refractory to ibrutinib, idelalisib  PM 3601 month ago

Preliminary results of the AIM trial of ibrutinib and venetoclax in mantle cell lymphoma

Loading........ 16 views Description: Constantine Tam, MBBS, MD from the Peter MacCallum Cancer Centre, Melbourne, Australia gives an overview of the preliminary results of the Phase II AIM study of ibrutinib and venetoclax (ABT-199) in ...
 Oncology Tube1 week ago ASCO 2016: Preliminary results of the AI...  Oncology Tube1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Ibrutinib
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less